🇺🇸 FDA
Pipeline program

Mometasone furoate drug formulation (MFF) 1

IRB201500381 - F

Phase 1 small_molecule completed

Quick answer

Mometasone furoate drug formulation (MFF) 1 for Hypersensitivity is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Hypersensitivity
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials